Group 1 - Standard Chartered Group and Alibaba Group signed a strategic cooperation memorandum to accelerate the integration of financial services and artificial intelligence technology using Alibaba Cloud's AI capabilities [2][5] - The Ministry of Agriculture and Rural Affairs plans to enhance regional cooperation in agricultural product consumption, focusing on collaborative assistance and mobilizing social forces for consumption activities [4] - Jiangsu Province's Medical Security Bureau announced pricing for brain-computer interface medical services, with non-invasive adaptation fees set at 966 yuan per session and invasive implantation fees at 6,600 yuan [4] Group 2 - The demand for 800G optical modules is surging, with Goldman Sachs predicting sales to reach 19.9 million and 33.5 million units in 2025 and 2026, respectively, representing increases of 10% and 58% from previous forecasts [7] - The optical module market is expected to grow significantly, with total market values projected at $12.73 billion and $19.37 billion for 2025 and 2026, reflecting year-on-year growth rates of 60% and 52% [7] - The human-shaped robot industry is set to accelerate production, with Tesla's CEO announcing plans for mass production of the Optimus robot starting in 2026, targeting an annual output of 1 million units within five years [9][10] Group 3 - Over 100 fund companies have made more than 5,400 purchases of their products this year, with net subscription amounts for equity funds exceeding 2.5 billion yuan [21] - Nearly 60 funds have achieved returns exceeding 60% this year, with the average return for active equity funds at 13.74% [22] - The issuance of equity funds is experiencing a resurgence, with 48 equity funds currently in issuance and 39 more set to launch soon [22]

Core Viewpoint - Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of its product, Sileweimi Monoclonal Antibody Injection, aimed at passive immunity for children and adolescents aged 2 to 18 suspected of rabies virus exposure [1][2]. Group 1: Drug Information - The drug Sileweimi Monoclonal Antibody Injection is a recombinant fully human bispecific antibody targeting the rabies virus (Rabies Virus, RABV) [2]. - It is classified as a Class 1 therapeutic biological product, with its action target being the glycoprotein (G protein) of RABV [2]. - The drug employs scFv+Fab structure and KIH technology to address heavy chain mismatch issues, and scFv fusion technology to resolve light chain mismatch issues [2]. - It is the world's first bispecific antibody for passive immunity against rabies, designed to ensure effectiveness against different strains or genotypes of the virus [2]. Group 2: Clinical Trial Approval - The clinical trial application for Sileweimi Monoclonal Antibody Injection has been approved for the indication of passive immunity in children and adolescents aged 2 to 18 suspected of rabies virus exposure [1][2]. - The approval is in accordance with the relevant requirements for drug registration under the Drug Administration Law of the People's Republic of China [1]. Group 3: Market Context - As of the announcement date, Sileweimi Monoclonal Antibody Injection is under review for new drug marketing application for adult passive immunity against suspected rabies virus exposure [2]. - Currently, only two rabies virus antibody drugs have been approved for marketing in China [2].

证券代码：688443 证券简称：智翔金泰 公告编号：2025-029 重庆智翔金泰生物制药股份有限公司 自愿披露关于斯乐韦米单抗注射液获得药物临床试 药品名称：斯乐韦米单抗注射液 申请事项：境内生产药品注册临床试验 申请人：重庆智翔金泰生物制药股份有限公司 受理号：CXSL2500414 适应症：2 岁至 18 岁以下儿童和青少年疑似狂犬病病毒暴露后的被动免疫 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，斯乐 韦米单抗注射液临床试验申请符合药品注册的有关要求，同意本品开展 2 岁至 验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，重庆智翔金泰生物制药股份有限公司（以下简称"公司"）收到国家 药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研产品斯乐韦 米单抗注射液 2 岁至 18 岁以下儿童和青少年疑似狂犬病病毒暴露后的被动免疫 适应症的临床试验申请获得批准。现将相关情况公告如下： 一、药品基本信息 斯乐韦米单抗注射液为 scFv+Fab 结构的双特异性抗体，使用 KIH ...

（编辑 任世碧） 证券日报网讯 7月29日晚间，智翔金泰发布公告称，近日，公司收到国家药品监督管理局核准签发的 《药物临床试验批准通知书》，公司在研产品斯乐韦米单抗注射液2岁至18岁以下儿童和青少年疑似狂 犬病病毒暴露后的被动免疫适应症的临床试验申请获得批准。 ...

Macro Dynamics - In the first half of the year, state-owned enterprises' total operating revenue decreased by 0.2% year-on-year, amounting to 4,074.96 billion yuan, while total profit fell by 3.1% to 218.25 billion yuan [1] - The taxes payable by state-owned enterprises also saw a decline of 0.8%, totaling 300.26 billion yuan [1] - As of the end of June, the asset-liability ratio of state-owned enterprises increased by 0.3 percentage points to 65.2% [1] Financial Institutions - Wang Xiaohang, former vice president of Ant Group, has been appointed as the Chief Technology Officer (CTO) of Ping An Group, bringing nearly 20 years of experience in the "finance + technology" sector [7] Market Data - The ChiNext Index rose by 1.86%, with strong performances in the pharmaceutical and steel sectors, while the overall market saw a trading volume exceeding 1.8 trillion yuan [8] - As of July 28, the financing balance on the Shanghai Stock Exchange reached 989.90 billion yuan, an increase of 11.71 billion yuan from the previous trading day [9] Company Dynamics - Apple announced the closure of its first direct store in Dalian, marking its first store closure in China, effective August 9, 2025 [11] - WuXi AppTec plans to adjust the upper limit of its share repurchase price from 90.72 yuan to 114.15 yuan per share, with its stock price rising significantly following the announcement [12] - Wanhua Chemical has resumed normal production at its facilities in Fujian after a maintenance shutdown [13] - China Chang'an Automobile has become the indirect controlling shareholder of Hunan Tianyan following a corporate restructuring [14] - Zhixiang Jintai received approval for clinical trials of its dual-specific antibody for passive immunity against rabies in children and adolescents [15]

人民财讯7月29日电，智翔金泰(688443)7月29日晚间公告，公司收到国家药品监督管理局核准签发的 《药物临床试验批准通知书》，公司在研产品斯乐韦米单抗注射液2岁至18岁以下儿童和青少年疑似狂 犬病病毒暴露后的被动免疫适应症的临床试验申请获得批准。 ...

Group 1 - The company, Zhixiang Jintai (688443.SH), has received approval from the National Medical Products Administration for the clinical trial of its product, Sileweimi Monoclonal Antibody Injection [1] - The clinical trial is aimed at evaluating the passive immunity indication for children and adolescents aged 2 to 18 years who are suspected of rabies virus exposure [1]

重庆智翔金泰生物制药股份有限公司 自愿披露关于斯乐韦米单抗注射液获得药物临床试 验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，重庆智翔金泰生物制药股份有限公司（以下简称"公司"）收到国家 药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研产品斯乐韦 米单抗注射液 2 岁至 18 岁以下儿童和青少年疑似狂犬病病毒暴露后的被动免疫 适应症的临床试验申请获得批准。现将相关情况公告如下： 一、药品基本信息 药品名称：斯乐韦米单抗注射液 申请事项：境内生产药品注册临床试验 证券代码：688443 证券简称：智翔金泰 公告编号：2025-029 斯乐韦米单抗注射液是全球首个用于狂犬病被动免疫的双特异性抗体，分子 设计满足 WHO 关于抗狂犬病病毒抗体开发的建议——采用针对不同抗原位点 的多株单抗组合成"鸡尾酒式"组合制剂，以保证对不同病毒株或病毒的不同基 因型的有效性。 截至本公告披露日，斯乐韦米单抗注射液用于成人疑似狂犬病病毒暴露后的 被动免疫适应症正处于新药上市申请审评中。经公开信息查询，国内仅有 ...

（原标题：智翔金泰(688443.SH)：斯乐韦米单抗注射液获药物临床试验批准） 智通财经APP讯，智翔金泰(688443.SH)公告，公司收到国家药品监督管理局核准签发的《药物临床试 验批准通知书》，公司在研产品斯乐韦米单抗注射液2岁至18岁以下儿童和青少年疑似狂犬病病毒暴露 后的被动免疫适应症的临床试验申请获得批准。 ...

每经AI快讯，7月29日，智翔金泰(688443.SH)公告称，公司在研产品斯乐韦米单抗注射液2岁至18岁以 下儿童和青少年疑似狂犬病病毒暴露后的被动免疫适应症的临床试验申请获得批准。斯乐韦米单抗注射 液是一款由公司自主研发的重组全人源抗狂犬病病毒双特异性抗体，注册分类为治疗用生物制品1类。 ...